Evidence
What the research shows
PT-141 (bremelanotide) was FDA-approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand Vyleesi. Its differentiator is central MC4R activation in the hypothalamus — it targets sexual desire itself, not just peripheral mechanics. That makes PT-141 especially notable in the peptide category: it is one of the few compounds here with formal FDA approval and a clearly defined on-demand use pattern. The standard researched dose is 1.75 mg subcutaneous, administered 45 minutes before activity, with a maximum of 8 doses per month. Interest remains high because it sits at the intersection of neuroendocrine signaling, libido support, and precision on-demand use rather than daily exposure.